

UNITED THERAPEUTICS Corp
Form 10-Q
July 28, 2016
[Table of Contents](#)

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2016

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from _____ to _____

Commission file number 0-26301

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of
Incorporation or Organization)

52-1984749

(I.R.S. Employer
Identification No.)

1040 Spring Street, Silver Spring, MD
(Address of Principal Executive Offices)

20910
(Zip Code)

(301) 608-9292

(Registrant's Telephone Number, Including Area Code)

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company. See definition of "large accelerated filer", "accelerated filer", and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Accelerated filer

Non-accelerated filer
(do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of the issuer's common stock, par value \$.01 per share, as of July 21, 2016 was 43,467,794.

Table of Contents

INDEX

	Page
<u>Part I.</u>	
<u>FINANCIAL INFORMATION (UNAUDITED)</u>	3
<u>Item 1.</u>	
<u>Consolidated Financial Statements</u>	3
<u>Consolidated Balance Sheets</u>	3
<u>Consolidated Statements of Operations</u>	4
<u>Consolidated Statements of Comprehensive Income (Loss)</u>	5
<u>Consolidated Statements of Cash Flows</u>	6
<u>Notes to Consolidated Financial Statements</u>	7
<u>Item 2.</u>	
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	19
<u>Item 3.</u>	
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	34
<u>Item 4.</u>	
<u>Controls and Procedures</u>	34
<u>Part II.</u>	
<u>OTHER INFORMATION</u>	35
<u>Item 1.</u>	
<u>Legal Proceedings</u>	35
<u>Item 1A.</u>	
<u>Risk Factors</u>	35
<u>Item 2.</u>	
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	52
<u>Item 6.</u>	
<u>Exhibits</u>	52
<u>SIGNATURES</u>	53

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. CONSOLIDATED FINANCIAL STATEMENTS****UNITED THERAPEUTICS CORPORATION****CONSOLIDATED BALANCE SHEETS****(In millions, except share data)**

	June 30, 2016 (Unaudited)	December 31, 2015
Assets		
Current assets:		
Cash and cash equivalents	\$ 837.5	\$ 831.8
Marketable investments	107.2	122.0
Accounts receivable, net of allowance of none for 2016 and 2015	238.1	192.8
Inventories, net	89.1	81.3
Other current assets	43.5	47.4
Total current assets	1,315.4	1,275.3
Marketable investments	3.9	38.0
Goodwill and other intangible assets, net	34.1	28.4
Property, plant, and equipment, net	490.6	495.8
Deferred tax assets, net	188.1	192.7
Other assets	169.4	154.2
Total assets	\$ 2,201.5	\$ 2,184.4
Liabilities and Stockholders Equity		
Current liabilities:		
Accounts payable and accrued expenses	\$ 124.0	\$ 103.4
Convertible notes	0.9	5.4
Share tracking awards plan	120.9	274.5
Other current liabilities	46.6	57.4
Total current liabilities	292.4	440.7
Other liabilities	92.0	144.0
Total liabilities	384.4	584.7
Commitments and contingencies		
Temporary equity	10.9	11.1
Stockholders equity:		
Preferred stock, par value \$.01, 10,000,000 shares authorized, no shares issued		
Series A junior participating preferred stock, par value \$.01, 100,000 shares authorized, no shares issued		
Common stock, par value \$.01, 245,000,000 shares authorized, 69,220,268 and 68,987,919 shares issued, and 43,732,565 and 45,760,845 shares outstanding at June 30, 2016 and December 31, 2015, respectively		
	0.7	0.7
Additional paid-in capital	1,826.7	1,790.6
Accumulated other comprehensive loss	(14.7)	(20.4)
	(2,167.9)	(1,902.1)

Edgar Filing: UNITED THERAPEUTICS Corp - Form 10-Q

Treasury stock, 25,487,703 and 23,227,074 shares at June 30, 2016 and December 31, 2015, respectively				
Retained earnings		2,161.4		1,719.8
Total stockholders' equity		1,806.2		1,588.6
Total liabilities and stockholders' equity	\$	2,201.5	\$	2,184.4

See accompanying notes to consolidated financial statements.

Table of Contents

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS

(In millions, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
	(Unaudited)		(Unaudited)	
Revenues:				
Net product sales	\$ 412.6	\$ 345.8	\$ 781.6	\$ 671.7
Other		1.4		3.0
Total revenues	412.6	347.2	781.6	674.7
Operating expenses:				
Cost of product sales	20.0	16.0	20.7	36.8
Research and development	35.2	49.4	34.8	159.6
Selling, general and administrative	72.2	110.0	77.2	321.3
Total operating expenses	127.4	175.4	132.7	517.7
Operating income	285.2	171.8	648.9	157.0
Other income (expense):				
Interest expense	(0.6)	(1.3)	(1.2)	(3.4)
Other, net	1.1	(2.1)	1.9	(2.0)
Total other income (expense), net	0.5	(3.4)	0.7	(5.4)
Income before income taxes	285.7	168.4	649.6	151.6
Income tax expense	(79.6)	(69.2)	(208.0)	(69.0)
Net income	\$ 206.1	\$ 99.2	\$ 441.6	\$ 82.6
Net income per common share:				
Basic	\$ 4.65	\$ 2.15	\$ 9.86	\$ 1.78
Diluted	\$ 4.39	\$ 1.91	\$ 9.24	\$ 1.57
Weighted average number of common shares outstanding:				
Basic	44.3	46.1	44.8	46.4
Diluted	46.9	51.9	47.8	52.5

See accompanying notes to consolidated financial statements.

Table of Contents

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In millions)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
	(Unaudited)		(Unaudited)	
Net income	\$ 206.1	\$ 99.2	\$ 441.6	\$ 82.6
Other comprehensive income (loss):				
Foreign currency translation (loss) gain	(2.2)	1.5	(1.8)	(1.6)
Defined benefit pension plan:				
Actuarial gain (loss) arising during period, net of tax	7.1		7.1	(2.1)
Less: amortization of actuarial gain and prior service cost included in net periodic pension cost, net of tax	0.2	0.2	0.4	0.5
Total defined benefit pension plan, net	7.3	0.2	7.5	(1.6)
Other comprehensive income (loss), net of tax	5.1	1.7	5.7	(3.2)
Comprehensive income	\$ 211.2	\$ 100.9	\$ 447.3	\$ 79.4

See accompanying notes to consolidated financial statements.

Table of Contents

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

	2016	Six Months Ended June 30, (Unaudited)	2015
Cash flows from operating activities:			
Net income	\$	441.6	\$ 82.6
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization		15.6	16.7
Share-based compensation (benefit) expense		(143.1)	281.8
Amortization of debt discount and debt issue costs		0.1	5.1
Amortization of discount or premium on investments		0.3	1.4
Other		1.1	(4.5)
Excess tax benefits from share-based compensation		(3.5)	(23.5)
Changes in operating assets and liabilities:			
Accounts receivable		(45.3)	(6.9)
Inventories		(8.8)	(1.9)
Accounts payable and accrued expenses		19.8	23.3
Other assets and liabilities		(26.3)	(224.0)
Net cash provided by operating activities		251.5	150.1
Cash flows from investing activities:			
Purchases of property, plant and equipment		(14.2)	(7.8)
Purchases of held-to-maturity investments		(0.8)	(61.3)
Maturities of held-to-maturity investments		49.6	172.8
Purchase of investments under the cost method, net		(7.6)	(4.2)
Purchase of investments under the equity method		(2.1)	
Intangible assets acquired		(5.2)	
Net cash provided by investing activities		19.7	99.5
Cash flows from financing activities:			
Principal payments of debt		(7.9)	(104.3)
Payments of debt issuance costs		(6.8)	
Payments to repurchase common stock		(259.7)	(336.8)
Proceeds from the exercise of stock options		5.0	24.4
Issuance of stock under employee stock purchase plan		2.2	1.9
Excess tax benefits from share-based compensation		3.5	23.5
Net cash used in financing activities		(263.7)	(391.3)
Effect of exchange rate changes on cash and cash equivalents		(1.8)	(1.6)
Net increase (decrease) in cash and cash equivalents		5.7	(143.3)
Cash and cash equivalents, beginning of period		831.8	397.7
Cash and cash equivalents, end of period	\$	837.5	\$ 254.4
Supplemental cash flow information:			
Cash paid for interest	\$	0.1	\$ 0.7
Cash paid for income taxes	\$	222.0	\$ 110.1
Non-cash investing and financing activities:			
Non-cash additions to property, plant and equipment	\$	3.4	\$ 1.4

Edgar Filing: UNITED THERAPEUTICS Corp - Form 10-Q

Issuance of common stock upon conversion of convertible notes	\$	6.1	\$	263.3
---	----	-----	----	-------

See accompanying notes to consolidated financial statements.

Table of Contents

UNITED THERAPEUTICS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2016

(UNAUDITED)

1. Organization and Business Description

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening diseases.

We have approval from the U.S. Food and Drug Administration (FDA) to market the following therapies: Remodulin® (treprostinil) Injection (Remodulin), Tyvaso® (treprostinil) Inhalation Solution (Tyvaso), Adcirca® (tadalafil) Tablets (Adcirca), Orenitram® (treprostinil) Extended-Release Tablets (Orenitram) and Unituxin® (dinutuximab) Injection (Unituxin). We commenced commercial sales of Unituxin in the United States during the third quarter of 2015. Remodulin has also been approved in various countries outside the United States, and Unituxin was granted marketing authorization by the European Medicines Agency in August 2015. Tyvaso is also approved in Israel.

As used in these notes to the consolidated financial statements, unless the context otherwise requires, the terms *we*, *us*, *our*, and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.

2. Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles (GAAP) for complete financial statements. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC on February 25, 2016.

In our management's opinion, the accompanying consolidated financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of June 30, 2016, statements of operations and comprehensive income (loss) for the three- and six-month periods ended June 30, 2016 and June 30, 2015 and cash flows for the six-month periods ended June 30, 2016 and June 30, 2015. Interim results are not necessarily indicative of results for an entire year.

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, *Revenue from Contracts with Customers* (ASU 2014-09). ASU 2014-09 will eliminate transaction-specific and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. ASU 2014-09 allows for either full retrospective or modified retrospective adoption. On July 9, 2015, the FASB issued ASU No. 2015-14, *Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date*, which (1) delays the effective date of ASU 2014-09 by one year to annual periods beginning after December 15, 2017; and (2) allows early adoption of the ASU by all entities as of the original effective date for public entities. We are evaluating the transition method we will elect and the effects of the adoption of this ASU on our financial statements.

In July 2015, the FASB issued ASU No. 2015-11, *Simplifying the Measurement of Inventory* (ASU 2015-11), which requires that inventory be measured at the lower of cost or net realizable value for entities using first-in, first-out or average cost methods. ASU 2015-11 should be applied prospectively and will be effective for fiscal years beginning after December 15,

Table of Contents

2016, and for interim periods within those fiscal years, with early adoption permitted. We are evaluating the effect of adoption on our financial statements.

In January 2016, the FASB issued ASU No. 2016-01, *Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities*, which requires equity investments to be measured at fair value through net income. Equity investments that are accounted for under the equity method are not impacted. ASU 2016-01 provides that equity investments without readily determinable fair values can be valued at cost minus impairment with a simplified impairment assessment using qualitative assessments. ASU 2016-01 requires separate presentation of the financial assets and liabilities by category and form. ASU 2016-01 should be applied prospectively and will be effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. Early adoption is not permitted except in limited circumstances. We are evaluating the effect of adoption on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, *Leases* (ASU 2016-02), which requires that organizations recognize lease assets and lease liabilities on the balance sheet. ASU 2016-02 also requires additional quantitative and qualitative disclosures that provide the amount, timing, and uncertainty of cash flows relating to lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018 using a modified retrospective approach. The modified retrospective approach requires retrospective application to the earliest period presented in the respective financial statements, provides certain practical expedients related to leases that commenced prior to the effective date and allows the use of hindsight when evaluating lease options. Early adoption is permitted. We are evaluating the effect of adoption on our financial statements.

In March 2016, the FASB issued ASU No. 2016-09, *Compensation - Stock Compensation* (ASU 2016-09), which serves to simplify the accounting for share-based payment transactions. ASU 2016-09 includes guidance on several aspects of the accounting for share-based payments, including the income tax consequences, forfeitures and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Early adoption is permitted. We are evaluating the effect of adoption on our financial statements.

3. Investments

Marketable Investments

Marketable investments classified as held-to-maturity consist of the following (in millions):

As of June 30, 2016	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Government-sponsored enterprises	\$ 44.2	\$ 0.1	\$	\$ 44.3
Corporate notes and bonds	66.9			66.9
Total	\$ 111.1	\$ 0.1	\$	\$ 111.2

Reported under the following captions on the consolidated balance sheet:

Edgar Filing: UNITED THERAPEUTICS Corp - Form 10-Q

Current marketable investments	\$	107.2
Noncurrent marketable investments		3.9
	\$	111.1

8

Table of Contents

As of December 31, 2015	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Government-sponsored enterprises	\$ 53.3	\$	\$ (0.2)	\$ 53.1
Corporate notes and bonds	106.7			106.7
Total	\$ 160.0	\$	\$ (0.2)	\$ 159.8
Reported under the following captions on the consolidated balance sheet:				
Current marketable investments	\$ 122.0			
Noncurrent marketable investments	38.0			
	\$ 160.0			

The following table summarizes gross unrealized losses and the length of time marketable investments have been in a continuous unrealized loss position (in millions):

	As of June 30, 2016		As of December 31, 2015	
	Fair Value	Gross Unrealized Loss	Fair Value	Gross Unrealized Loss
Government-sponsored enterprises:				
Continuous unrealized loss position less than one year	\$	\$	\$ 48.1	\$ (0.2)
Continuous unrealized loss position greater than one year			48.1	(0.2)
Corporate notes and bonds:				
Continuous unrealized loss position less than one year	3.0		63.8	
Continuous unrealized loss position greater than one year				
Total	\$ 3.0	\$	\$ 111.9	\$ (0.2)

We attribute gross unrealized losses pertaining to our held-to-maturity securities as of December 31, 2015 to the variability in related market interest rates. We do not intend to sell these securities, nor is it more likely than not that we will be required to sell them prior to the end of their contractual terms. Furthermore, we do not believe that these securities expose us to undue market risk or counterparty credit risk. As such, we do not consider these securities to be other than temporarily impaired.

The following table summarizes the contractual maturities of held-to-maturity marketable investments (in millions):

	June 30, 2016	
	Amortized Cost	Fair Value
Due in less than one year	\$ 107.2	\$ 107.3
Due in one to two years	3.9	3.9
Total	\$ 111.1	\$ 111.2

Table of Contents

4. Fair Value Measurements

We account for certain assets and liabilities at fair value and rank these assets within a fair value hierarchy (Level 1, Level 2 or Level 3). Our other current assets and our current liabilities have fair values that approximate their carrying values. Assets and liabilities subject to fair value measurements are as follows (in millions):

	As of June 30, 2016			Balance
	Level 1	Level 2	Level 3	
Assets				